FY2025 Earnings Estimate for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Equities research analysts at Zacks Research decreased their FY2025 earnings estimates for Bruker in a research note issued on Monday, February 10th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $2.73 for the year, down from their previous estimate of $2.76. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.92 EPS, Q4 2026 earnings at $0.84 EPS and FY2026 earnings at $3.32 EPS.

Several other research analysts also recently commented on the stock. Bank of America lifted their price target on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Citigroup decreased their target price on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. TD Cowen decreased their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research note on Thursday, December 5th. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average target price of $74.09.

Bruker Trading Up 2.0 %

BRKR stock opened at $51.65 on Wednesday. The company has a market capitalization of $7.83 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. Bruker has a one year low of $48.07 and a one year high of $94.86. The company’s 50 day moving average price is $57.88 and its two-hundred day moving average price is $60.77. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66.

Institutional Trading of Bruker

A number of hedge funds have recently modified their holdings of BRKR. Sanctuary Advisors LLC bought a new stake in shares of Bruker during the 2nd quarter valued at $296,000. GAMMA Investing LLC boosted its holdings in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares in the last quarter. CWM LLC boosted its holdings in shares of Bruker by 191.9% during the 3rd quarter. CWM LLC now owns 13,942 shares of the medical research company’s stock valued at $963,000 after buying an additional 9,165 shares in the last quarter. UMB Bank n.a. boosted its stake in Bruker by 115.3% in the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Finally, Rheos Capital Works Inc. bought a new position in Bruker in the 3rd quarter worth about $3,453,000. Institutional investors own 79.52% of the company’s stock.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien bought 100,000 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 28.30% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.